Probiotics in Clostridium difficile infection

Journal of Clinical Gastroenterology

Volumn 45, Issue SUPPL. 3, 2011, Pages

  Na, Xi ^a   Kelly, Ciaran ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Clostridium difficile infection; probiotics; Saccharomyces boulardii

Indexed keywords

PROBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; CLOSTRIDIUM DIFFICILE INFECTION; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; LACTOBACILLUS; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES BOULARDII; SYSTEMATIC REVIEW (TOPIC);

ADULT; CHILD; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; LACTOBACILLUS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SACCHAROMYCES; TREATMENT OUTCOME;

EID: 80054092791     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31822ec787     Document Type: Conference Paper

References (59)

1. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330:257-262.
2. Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346-353.
3. Vonberg RP, Reichardt C, Behnke M, et al. Costs of nosocomial Clostridium difficile-associated diarrhoea. J Hosp Infect. 2008;70:15-20.
4. Do AN, Fridkin SK, Yechouron A, et al. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998;26:954-959.
5. Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, doubleblinded trial. Clin Infect Dis. 1997;24:324-333.
6. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis. 2008;46(suppl 1):S32-S42.
7. Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhoea. Gut. 2001;49:152-153.
8. Maroo S, Lamont JT. Recurrent Clostridium difficile. Gastroenterology. 2006;130:1311-1316.
9. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769-1775.
10. McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999;20:43-50.
11. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-307.
12. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174-180.
13. De La Cochetiere MF, Durand T, Lalande V, et al. Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile. Microb Ecol. 2008;56:395-402.
14. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594.
15. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197:435-438.
16. Wilson KH. The microecology of Clostridium difficile. Clin Infect Dis. 1993;16(suppl 4):S214-S218.
17. Hall IC, O'Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child. 1935;49:390-402.
18. Antonopoulos DA, Huse SM, Morrison HG, et al. Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun. 2009;77:2367-2375.
19. Katz JA. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. J Clin Gastroenterol. 2006;40:249-255.
20. Surawicz CM. Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2008;42(suppl 2):S64-S70.
21. Czerucka D, Rampal P. Effect of Saccharomyces boulardii on cAMP-and Ca2+-dependent Cl-secretion in T84 cells. Dig Dis Sci. 1999;44:2359-2368.
22. Buts JP, Bernasconi P, Vaerman JP, Dive C. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci. 1990;35:251-256.
23. Dahan S, Dalmasso G, Imbert V, et al. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coliinduced signaling pathways in T84 cells. Infect Immun. 2003;71:766-773.
24. Castagliuolo I, LaMont JT, Nikulasson ST, et al. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun. 1996;64:5225-5232.
25. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993;104:1108-1115.
26. Chen X, Kelly CP. Saccharomyces species. In: Versalovic J, Wilson M, eds. Therapeutic Microbiology: Probiotics and Other Strategies. Washington DC: American Society of Microbiology; 2006:51-60.
27. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913-1918.
28. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31:1012-1017.
29. Conway PL, Gorbach SL, Goldin BR. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci. 1987;70:1-12.
30. Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet. 1987;2:1519.
31. Biller JA, Katz AJ, Flores AF, et al. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr. 1995;21:224-226.
32. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol. 2005;54:905-906.
33. Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis. 2003;35:365-367.
34. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ. 2007;335:80.
35. Wilcox MH, Sandoe JA. Probiotics and diarrhea: data are not widely applicable. BMJ. 2007;335:171.
36. Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010;105:1636-1641.
37. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83:1256-1264. quiz 446-447.
38. Kunz AN, Fairchok MP, Noel JM. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005;116:517. author reply 8.
39. Husni RN, Gordon SM, Washington JA, et al. Lactobacillus bacteremia and endocarditis: review of 45 cases. Clin Infect Dis. 1997;25:1048-1055.
40. Mackay AD, Taylor MB, Kibbler CC, et al. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect. 1999;5:290-292.
41. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis. 1999;28:1159-1160.
42. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40:1625-1634.
43. Cassone M, Serra P, Mondello F, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol. 2003;41:5340-5343.
44. Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis. 2000;19:16-20.
45. Graf C, Gavazzi G. Saccharomyces cerevisiae fungemia in an immunocompromised patient not treated with Saccharomyces boulardii preparation. J Infect. 2007;54:310-311.
46. Lherm T, Monet C, Nougiere B, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med. 2002;28:797-801.
47. Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med. 1998;105:71-72.
48. Elmer GW. Probiotics: "living drugs". Am J Health Syst Pharm. 2001;58:1101-1109.
49. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101:812-822.
50. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;CD004611.
51. Elmer GW, McFarland LV, Surawicz CM, et al. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther. 1999;13:1663-1668.
52. Dendukuri N, Costa V, McGregor M, et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ. 2005;173:167-170.
53. Segarra-Newnham M. Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii. Ann Pharmacother. 2007;41:1212-1221.
54. Tung JM, Dolovich LR, Lee CH. Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review. Can J Gastroenterol. 2009;23:817-821.
55. Sambol SP, Merrigan MM, Tang JK, et al. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis. 2002;186:1781-1789.
56. Seal D, Borriello SP, Barclay F, et al. Treatment of relapsing Clostridium difficile diarrhoea by administration of a nontoxigenic strain. Eur J Clin Microbiol. 1987;6:51-53.
57. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-455.
58. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15:1067-1079.
59. Orrhage K, Sjostedt S, Nord CE. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. J Antimicrob Chemother. 2000;46:603-612.